The lack of a meaningful P/E or EV/EBITDA multiple underscores the market's focus on binary clinical outcomes rather than current earnings power. Investors should monitor whether the current valuation adequately accounts for the potential long-term value of the DART platform or if it remains overly sensitive to near-term liquidity concerns.

The erratic nature of these returns is largely driven by the timing of milestone-based revenue rather than operational efficiency. This suggests that until the company can transition to a more predictable commercial revenue stream, ROIC will likely remain a secondary metric for assessing long-term value creation.

The significant swings in DSO and DPO suggest that the company's ability to manage its cash cycle is secondary to the unpredictable nature of its partnership-driven revenue model. This volatility warrants further investigation into whether management can stabilize these metrics as the pipeline matures.

The negative interest coverage ratio suggests that the company is not currently generating sufficient operating income to service its debt obligations comfortably. Investors should monitor the company's ability to secure non-dilutive capital, as the current leverage profile appears increasingly unsustainable without a successful clinical readout.